Approval Of Baricitinib For Patchy Baldness Validates Clinical Patch For This Small-Cap Stock

Vandana Singh
1 min read
0
In this article:

  • Olumiant (baricitinib), a Janus kinase (JAK) inhibitor, was developed by Incyte Corp (NASDAQ: INCY) and launched in collaboration with Eli Lilly And Co (NYSE: LLY), received FDA approval for hair loss disorder known as alopecia areata (AA).

  • Olumiant was first approved for the treatment of rheumatoid arthritis (RA) in 2018.

  • The above nod is expected to provide a template for Equillium Inc (NASDAQ: EQ) EQ-101 in this indication, says HC Wainwright.

  • Related: Lilly-Incyte Snag FDA Nod For Patchy Hair Loss Treatment — Smaller Rival's Stock Shoots Up In Sympathy.

  • The analysts write that the size and design of the pivotal trials with baricitinib in AA are manageable and should prove relatively cost-effective if EQ-101 is advanced into Phase 3 studies.

  • EQ-101's niche to exploit impact on AA may be eclipsed even after clinically meaningful and competitive data, as JAK inhibitors have come under scrutiny for safety reasons.

  • The analysts reiterate a Buy rating and a price target of $15 per share on EQ.

  • "From our vantage point, investors continue to ignore the potential of the Bioniz portfolio that Equillium acquired earlier this year, including EQ-101," writes HC Wainwright.

  • Related: Equillium Adds Three Drugs To Its Pipeline Via Bioniz Acquisition.

  • Price Action: EQ shares are up 2.97% at $2.08 during the market session on the last check Tuesday.

Latest Ratings for EQ

Date

Firm

Action

From

To

Jan 2022

SVB Leerink

Maintains

Outperform

Sep 2021

Cantor Fitzgerald

Initiates Coverage On

Overweight

Mar 2021

JonesTrading

Initiates Coverage On

Buy

View More Analyst Ratings for EQ

View the Latest Analyst Ratings

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement

Recommended Stories